

12

**EUROPEAN PATENT APPLICATION**

21 Application number: 86105916.0

51 Int. Cl.<sup>3</sup>: **C 12 N 5/00**  
**C 12 N 15/00, G 01 N 33/566**

22 Date of filing: 29.04.86

30 Priority: 01.05.85 JP 92299/85  
08.07.85 JP 148327/85  
10.07.85 JP 150047/85  
05.08.85 JP 171215/85

43 Date of publication of application:  
03.12.86 Bulletin 86/49

88 Date of deferred publication of search report: 14.09.88

84 Designated Contracting States:  
DE FR GB IT

71 Applicant: Asahi Kasei Kogyo Kabushiki Kaisha  
2-6, Dojimahama 1-chome Kita-ku  
Osaka-shi Osaka 530(JP)

72 Inventor: Kaieda, Takeji  
168-52, Obuchi  
Fuji-shi Shizuoka-ken(JP)

72 Inventor: Imafuku, Hiroshi  
452-15, Ishizaka  
Fuji-shi Shizuoka-ken(JP)

72 Inventor: Yamawaki, Naokuni  
3-7-10, Fujimidai  
Fuji-shi Shizuoka-ken(JP)

74 Representative: Boeters, Hans Dietrich, Dr.  
Boeters, Bauer & Partner Thomas-Wimmer-Ring 14  
D-8000 München 22(DE)

54 **A cloned T cell capable of recognizing tumors and a T cell antigen receptor.**

57 There is disclosed a cloned T cell capable of recognizing a wide variety of tumors and a T cell antigen receptor capable of binding to a wide variety of tumors. The cloned T cell of the present invention is useful to obtain the T cell antigen receptor of the present invention. When a marker or cytotoxin is bonded to the T cell antigen receptor, the resulting T cell antigen receptor can be advantageously utilized for the clinical examination to determine whether a patient suffers from tumours or for the treatment of tumors.



European Patent  
Office

# EUROPEAN SEARCH REPORT

0203403

Application Number

EP 86 10 5916

| DOCUMENTS CONSIDERED TO BE RELEVANT   |  |  |  |
|---|--|--|--|
| Category  | Citation of document with indication, where appropriate, of relevant passages  | Relevant to claim                              | CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)                 |
| X, D  | JOURNAL OF EXPERIMENTAL MEDICINE, vol. 158, November 1983, pages 1547-1560, The Rockefeller University Press; T. HERCEND et al.: "Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines"<br>* Whole document * | 1, 3, 5, 7, 9, 10, 12, 14, 15                  | C 12 N 5/00<br>C 12 N 15/00<br>G 01 N 33/566                   |
| A, D  | NATURE, vol. 309, 28th June 1984, pages 757-762; H. SAITO et al.: "Complete primary structure of a heterodimeric T-cell receptor deduced from cDNA sequences"  |  |  |
| A, D  | JOURNAL OF EXPERIMENTAL MEDICINE, vol. 157, February 1983, pages 705-719, The Rockefeller University Press; S.C. MEUER et al.: "Clonotypic structures involved in antigen-specific human T cell function"  |  |  |
| A, D  | EP-A-0 149 548 (ONTARIO CANCER INSTITUTE)  |  |  |
| The present search report has been drawn up for all claims  |  |  | TECHNICAL FIELDS SEARCHED (Int. Cl. 4)<br><br>C 12 N<br>G 01 N |
| Place of search<br>THE HAGUE  |  | Date of completion of the search<br>13-06-1988 | Examiner<br>ALVAREZ Y ALVAREZ C.                               |
| <b>CATEGORY OF CITED DOCUMENTS</b><br>X : particularly relevant if taken alone<br>Y : particularly relevant if combined with another document of the same category<br>A : technological background<br>O : non-written disclosure<br>P : intermediate document<br>T : theory or principle underlying the invention<br>E : earlier patent document, but published on, or after the filing date<br>D : document cited in the application<br>L : document cited for other reasons<br>& : member of the same patent family, corresponding document |  |  |  |

(12)

**EUROPEAN PATENT APPLICATION**

(21) Application number: **86105916.0**

(51) Int. Cl.: **C 12 N 5/00, C 12 N 15/00,**  
**G 01 N 33/566**

(22) Date of filing: **29.04.86**

(30) Priority: **01.05.85 JP 92299/85**  
**08.07.85 JP 148327/85**  
**10.07.85 JP 150047/85**  
**05.08.85 JP 171215/85**

(43) Date of publication of application: **03.12.86**  
**Bulletin 86/49**

(84) Designated Contracting States: **DE FR GB IT**

(71) Applicant: **Asahi Kasei Kogyo Kabushiki Kaisha, 2-6,**  
**Dojimahama 1-chome Kita-ku, Osaka-shi Osaka 530 (JP)**

(72) Inventor: **Kaieda, Takeji, 168-52, Obuchi, Fuji-shi**  
**Shizuoka-ken (JP)**  
Inventor: **Imafuku, Hiroshi, 452-15, Ishizaka, Fuji-shi**  
**Shizuoka-ken (JP)**  
Inventor: **Yamawaki, Naokuni, 3-7-10, Fujimidai, Fuji-shi**  
**Shizuoka-ken (JP)**

(74) Representative: **Boeters, Hans Dietrich, Dr., Boeters,**  
**Bauer & Partner Thomas-Wimmer-Ring 14,**  
**D-8000 München 22 (DE)**

(54) **A cloned T cell capable of recognizing tumors and a T cell antigen receptor.**

(57) There is disclosed a cloned T cell capable of recognizing a wide variety of tumors and a T cell antigen receptor capable of binding to a wide variety of tumors. The cloned T cell of the present invention is useful to obtain the T cell antigen receptor of the present invention. When a marker or cytotoxin is bonded to the T cell antigen receptor, the resulting T cell antigen receptor can be advantageously utilized for the clinical examination to determine whether a patient suffers from tumors or for the treatment of tumors.

**EP 0 203 403 A2**

This invention relates to a cloned T cell capable of recognizing tumors. More particularly, the present invention relates to a cloned T cell which is capable of recognizing plural kinds of tumor cells. The present invention also relates to a method for producing the cloned T cell and to a T cell antigen receptor capable of binding to tumors. Further, the present invention relates to a marker-bonded T cell antigen receptor and a cytotoxin-bonded T cell antigen receptor.

Heretofore, studies have been made of the identification and quantitative analysis of antigens using antibodies, inter alia monoclonal antibodies. The antibodies are antigen-recognizing substances of B lymphocytes (hereinafter often referred to as "B cells"). Especially, with respect to a tumor antigen which is produced by a tumor cell, studies have been made to obtain an antibody against a tumor antigen. Such an antibody binds to only a tumor antigen held on a tumor cell. Therefore, an antibody against a tumor cell can be utilized for clinical examination to determine whether a patient suffers from the tumor. Further, when a cytotoxin is bonded to the antibody, the cytotoxin carried by the antibody is caused to act specifically on the tumor and, as a result, the tumor

is destroyed by the action of the cytotoxin. That is, the antibody can be utilized for the treatment of a tumor. In this connection, from the standpoint of the clinical examination and treatment of tumors, it is  
5 desired in the art to obtain an antibody which is capable of binding to a wide variety of tumors. However, such an antibody have hitherto not been obtained.

On the other hand, according to the progress in  
10 the field of immunology, it has been found that the antigen recognition of T lymphocytes (hereinafter often referred to as "T cells") is effected by the function of a T cell antigen receptor. Therefore, it is expected that a T cell antigen receptor can also be  
15 utilized for the clinic examination to determine whether a patient suffers from a tumor and for the treatment of tumor. With respect to the T cell antigen receptor, Tonegawa et al have reported the basic structure of a T cell antigen receptor[S. Tonegawa et  
20 al, Nature, 757, 309 (1984)]. According to the report of Tonegawa et al, there are about one million kinds of T cell antigen receptors. Tonegawa et al have also determined the base sequence of a DNA coding for one of mouse T cell antigen receptors. Further, Mak Tak

et al have determined the base sequence of a DNA  
coding for one of human T cell antigen receptors  
(European Patent Application Publication No. 0 149  
548). However, there has not been obtained a T cell  
5 antigen receptor which is capable of binding to a wide  
variety of tumors. Moreover, it is extremely  
difficult to obtain a sufficient amount of T cell  
antigen receptors, because T cells which are the  
sources of the T cell antigen receptors cannot be  
10 multiplied. For this reason, the study of the T cell  
antigen receptors has been delayed.

The present inventors have made extensive and  
intensive studies to cope with the above-mentioned  
problem and to obtain a T cell antigen receptor which  
15 is capable of binding to a wide variety of tumors. To  
this end, the present inventors have effected cloning  
of cytotoxic T cells. As a result, it has been found  
that there are cytotoxic T cells which are capable of  
reacting with and killing a wide variety of tumors but  
20 do not react with and kill normal cells. Then, the  
present inventors have made efforts and succeeded in  
obtaining clones of such cytotoxic T cells. The  
present inventors have also succeeded in obtaining  
clones of helper T cells which are capable of reacting  
25 with a wide variety of tumors to produce lymphokines,

but do not react with normal cells. Further, it has been found that T cell antigen receptors obtained from the clones can bind to a wide variety of tumors but do not bind to normal cells. Moreover, the present  
5 inventor have found that the T cell antigen receptors containing a cytotoxin bonded thereto can be advantageously used for killing tumor cells with no toxic effect upon normal cells, and that the T cell antigen receptors containing a marker bonded thereto can be  
10 advantageously used for the identification and quantitative analysis of tumor antigens such as cell membrane-binding tumor antigens and cell-free tumor antigens. The present invention has been made such novel findings.

15 Therefore, it is an object of the present invention to provide a cloned T cell which can recognize a wide variety of tumors.

It is another object of the present invention to provide a T cell antigen receptor which can bind to a  
20 wide variety of tumors.

It is a further object of the present invention to provide a marker-bonded T cell antigen receptor which can be advantageously used for the clinical examination to determine whether a patient suffers

from a tumor.

It is still a further object of the present invention to provide a cytotoxin-bonded T cell antigen receptor which can be advantageously used for treating tumors.

The foregoing and other objects, features and advantages of the present invention will be apparent from the following detailed description.

Essentially, according to the present invention, there is provided a cloned T cell which is capable of recognizing plural kinds of tumor cells.

The cloned T cell of the present invention is derived from T cells of a mammal such as human, mouse, rat, rabbit and guinea pig. As the T cells, there may be mentioned helper T cells and cytotoxic T cells. When the cloned T cell of the present invention is derived from a helper T cell, the cloned T cell reacts with tumor cells and produces lymphokines etc. (helper activity). When the cloned T cell of the present invention is derived from a cytotoxic T cell, the cloned T cell reacts with tumor cells and kills the tumor cells (cytotoxicity). That is, the term "recognizing tumor cells" used herein means that the cloned T cell exhibits helper activity or cytotoxicity as mentioned above.



The cloned T cell of the present invention can recognize plural kinds of tumor cells. However, the cloned T cell of the present invention does not exhibit toxic activity upon normal cells. As the tumor cells, there may be mentioned, for example, solid tumors such as human gastric tumor cell lines MKN-1, MKN-7 and KATO-III, human lung tumor cell lines PC-1, PC-9, PC-10, PC-13 and PC-14, human colon tumor cell lines C-1 and M7609, human rectal tumor cell lines CaR-1 and S-7512, a human cystic tumor cell line H-1, human hepatoma cell lines HLE and HLF, human bladder tumor cell lines NBT-2 and KU-1, a human throat tumor cell line KB, human kidney tumor cell lines W-2 and NRC-12, human breast tumor cell lines HBC-4 and HBC-6, a human uterine tumor cell line HeLa, human melanoma cell lines HMV-1 and HMV-2, human neuroblast tumor cell lines GOTO and SYM-I, a human ovarian tumor cell line YS-K, a human muscular tumor cell line KYM-I and the like. The cloned T cell of the present invention is defined to be capable of recognizing at least two kinds of tumor cell. Of course, the more kinds of tumor cells the cloned T cell can recognize, the better the cloned T cell.

As specific examples of the cloned T cell of the present invention, there may be mentioned the following cloned T cells.

5 (1) A cloned T cell which is capable of recognizing at least two human gastric tumor cell lines MKN-1 and KATO-III but does not recognize normal human lymphocytes and fetus-derived fibroblast (this cloned T cell seems to be specific for gastric tumors).

10 (2) A cloned T cell which is capable of recognizing at least two human colon tumor cell lines C-1 and M7609 but does not recognize normal human lymphocytes (this cloned T cell seems to be specific for colon tumors).

15 (3) A cloned T cell which is capable of recognizing at least two human rectal tumor cell lines CaR-1 and S-7512 but does not recognize normal human lymphocytes (this cloned T cell seems to be specific for rectal tumors).

20 (4) A cloned T cell which is capable of recognizing at least two human hepatoma cell lines HLE and HLF but does not recognize normal human lymphocytes (this cloned T cell seems to be specific for hepatomas).

25 (5) A cloned T cell which is capable of recognizing at least two human bladder tumor cell lines NBT-2 and KU-1 but does not recognize normal human lymphocytes

(this cloned T cell seems to be specific for bladder tumors).

5 (6) A cloned T cell which is capable of recognizing at least two human kidney tumor cell lines W-2 and NRC-12 but does not recognize normal human lymphocytes (this cloned T cell seems to be specific for kidney tumors).

10 (7) A cloned T cell which is capable of recognizing at least two human breast tumor cell lines HBC-4 and HBC-6 but does not recognize normal human lymphocytes (this cloned T cell seems to be specific for breast tumors).

15 (8) A cloned T cell which is capable of recognizing at least five human lung tumor cell lines PC-1, PC-9, PC-10, PC-13 and PC-14 but does not recognize normal human lymphocytes and fetus-derived fibroblasts (this cloned T cell seems to be specific for lung tumors).

20 (9) A cloned T cell which is capable of recognizing at least human lung tumor cell lines PC-10 and PC-14, human gastric tumor cell lines MKN-1 and KATO-III, and a human bladder tumor cell line BT-2 but does not recognize normal human lymphocytes (this cloned T cell seems to have a specificity for various kinds of tumors).

Unlike natural T cells which cannot be multiplied, the cloned T cell of the present invention can be multiplied. As the cloned T cell of the present invention, there may be mentioned two types of cloned T cells, i.e., a cloned T cell which may be obtained by activating a natural T cell by an activator such as lectin, interleukin 2, etc. and a cloned T cell which is a hybridoma comprising a T cell and a T lymphoma. The former requires interleukin 2 as a growth stimulator for its growth, but the latter does not require the growth stimulator for its growth.

In the case where the cloned T cell of the present invention is a hybridoma, as the T lymphoma, there may be mentioned, for example, 8-azaguanine resistant strains derived from human T lymphomas such as CEM, Jurkat, HPB-ALL, HPB-MLT, Molt-3 and Malt-4. Of them, 8-azaguanine resistant strains derived from CEM and Jurkat are more preferred from the standpoint of efficiency of cell fusion. The cell fusion will be explained later. The above-mentioned T lymphomas are publicly available, for example, from the facilities described in Protein, Nucleic Acid, Enzyme, 23 (6), 291-304 (1978). The T lymphoma CEM is also available from the Division of Chemical Toxicology and Immunochemistry, Faculty of Pharmaceutical Science,

University of Tokyo, Bunkyo-ku, Tokyo, Japan. The T lymphoma Jurkat is also available from the Department of Medicine and the Howard Hughes Medical Institute, University of California, San Francisco, California 94143, U.S.A. [Arthur Weiss & John D. Stobo, J. Exp. Med., 160, 128 (1984)]. The 8-azaguanine resistant strains may be prepared from the above-mentioned T lymphomas according to the method described in, for example, Japanese Patent Application Laid-open Specification No. 57-206383.

In another aspect of the present invention, there is provided a method for producing a cloned T cell which is capable of recognizing plural kinds of tumor cells, comprising:

- (a) activating lymphocytes by an activator selected from the group consisting of a tumor cell, a lectin, interleukin 2 and mixtures thereof to obtain activated lymphocytes,
- (b) subjecting the activated lymphocytes to cloning in a medium containing interleukin 2 to obtain cloned lymphocytes, and
- (c) subjecting the cloned lymphocytes to screening to isolate a T cell capable of recognizing plural kinds of tumor cells from said cloned lymphocytes.

The lymphocytes to be used in the method of the present invention may be obtained from peripheral blood, spleen or lymph node of a mammal such as human, mouse, rat, rabbit and guinea pig. Among the peripheral blood, spleen and lymph node, the peripheral blood is more preferred because the peripheral blood can be obtained from the living body of a mammal more easily than the spleen and lymph node. The lymphocytes are activated using an activator. As the activator, there may be mentioned a tumor cell, a lectin, interleukin 2 and mixtures thereof. Of them, a lectin or interleukin 2 is more preferred because by the use of a lectin or interleukin 2, these may be obtained cloned T cells having various specificities. As the tumor cell to be used as the activator, there may be mentioned, for example, human tumor cell lines as mentioned before. As the lectin, there may be mentioned, for example, PHA derived from Phaseolus vulgaris, Con A derived from Concanavalia ensiformis, WFA derived from Wisteria aoribanba, LCH derived from Lens culinaris and PWM derived from Phytolacca americana. Of them, PHA and PWM are more preferred from the standpoint of activity for activating T cells capable of recognizing tumor cells.

The activated lymphocytes are subjected to

cloning. The cloning may be effected according to the method described in T. Kaieda, J. Immunol., 129, 46 (1982). Illustratively stated, the activated lymphocytes are suspended in a medium containing interleukin 2, and the thus obtained suspension is poured into each well of a microplate so that each well contains one activated lymphocyte. The microplate is then incubated to multiply each lymphocyte. Thus, cloned lymphocytes are obtained.

Then, the cloned lymphocytes are subjected to screening. The screening is effected as follows. Each cloned lymphocyte is cultured together with a tumor cell. After culturing, selection is made with respect to cloned T cells which exhibit helper activity and, hence, are capable of producing lymphokines such as interleukin 2, interferon, etc. or cloned T cells which exhibit cytotoxicity against the tumor cell. The methods for determining the cytotoxicity and the helper activity will be mentioned later.

Thus, there are obtained cloned T cells of the present invention which require interleukin 2 as a growth stimulator for its growth.

The thus obtained cloned T cell may, as mentioned before, be fused with a T lymphoma to form a hybridoma

so that the cloned T cell may grow without a growth stimulator and can be multiplied easily.

The cell fusion of a cloned T cell and a T lymphoma may be effected according to a customary method [M. Okada, N. Yoshimura, T. Kaieda, Proc. Natl. Acad. Sci., 78, 7717 (1981)]. Illustratively stated, the cell fusion may be carried out in a customary medium containing a fusion accelerator. As the fusion accelerator, there may be mentioned, for example, polyethylene glycol (hereinafter often referred to as "PEG"), etc. The amount ratio of the cells of a T lymphoma to the cells of the cloned T cell may generally be about 1 to 10. The cells of the cloned T cell and T lymphoma are mixed in the medium at room temperature. The resulting mixture is subjected to centrifugation to separate the mixture into cells and a supernatant. The supernatant is discarded. To the cells is added a medium containing PEG which has been heated at 37 °C, followed by stirring to initiate the cell fusion. The mixture is incubated to advance the fusion reaction. During the incubation, the medium is changed to a fresh medium, that is, the mixture is subjected to centrifugation to separate the mixture into cells and a supernatant, and then the supernatant is discarded, and to the cells is added a medium.



The change of the medium is effected at predetermined intervals. Thus, hybridoma is formed.

5 The hybridoma is isolated from the cells remaining unfused. The isolation is effected by culturing the cell mixture containing the hybridomas and the cells remaining unfused in a customary medium for hybridoma selection. The medium for hybridoma selection is a medium in which the hybridoma can grow but the unfused cells cannot grow. As such a medium, 10 there may be mentioned, for example, a medium containing hypoxanthine, aminopterin and thymidine (hereinafter referred to as "HAT medium"). As the HAT medium, there may be mentioned, for example, a medium containing 10 % fetal calf serum (FCS),  $2 \times 10^{-7}$  M aminopterin,  $1 \times 10^{-4}$  M hypoxanthine,  $1.6 \times 10^{-3}$  M 15 thymidine and  $3 \times 10^{-6}$  M glycine. Culturing of the cells in a HAT medium is effected according to a customary limiting dilution method for a sufficient period of time so that cells other than the hybridoma dies. Thus, the intended hybridoma can be selectively 20 obtained.

The thus obtained hybridoma is different from the original 8-azaguanine resistant T lymphoma and the original cloned T cell with respect to karyotype

(number of chromosomes), mitogen response, lymphokine producibility, etc. The hybridoma may be multiplied and stored in a HAT medium as mentioned above.

5 However, it is preferred that after the selection of the hybridoma, the hybridoma be cultured in a customary HT medium containing hypoxanthine and thymidine and, then, the hybridoma be transferred into a customary growth medium.

10 The hybridoma of the present invention may also be prepared by a method in which lymphocytes are fused with T lymphomas to obtain hybridomas and, then, the hybridomas are subjected to screening to obtain a hybridodma capable of recognizing tumor cells. That is, in an even another aspect of the present inven-  
15 tion, there is provided a method for producing a cloned T cell which is capable of recognizing plural kinds of tumor cells, comprising:

- (a) fusing lymphocytes with cells of a T lymphoma to form hybridomas, and
- 20 (b) subjecting the hybridomas to screening to isolate a T cell capable of recognizing plural kinds of tumor cells from said hybridomas.

As the lymphocytes to be fused with cells of a T lymphoma, there may be employed the lymphocytes as  
25 mentioned before. As the T lymphoma, there may be

employed 8-azaguanine resistant strains as mentioned before. The cell fusion may be effected in the same manner as mentioned before. Thus, there are obtained a hybridoma mixture including hybridomas which can  
5 recognize tumor cells and hybridomas which cannot recognize tumor cells. From the hybridoma mixture, the hybridomas capable of recognizing tumor cells are isolated by the screening method as mentioned before.

Thus, a cloned T cell of the present invention is  
10 obtained in the form of a hybridoma.

In a further aspect of the present invention, there is provided a T cell antigen receptor which is capable of binding to plural kinds of tumor cells.

The T cell antigen receptor of the present invention is a receptor which is produced by a T cell  
15 capable of recognizing tumors and is bonded to the surface of the T cell. The T cell antigen receptor of the present invention may be obtained from the above-mentioned cloned T cell of the present invention.  
20 From the standpoint of acceptability to a human body, it is preferred to obtain the T cell antigen receptor from the cloned T cells derived from human. The method for producing a T cell antigen receptor from the cloned T cell will be explained below.

First, the cloned T cells are cultured in a customary medium or in the body of an X ray-irradiated animal on a large scale. The cloned T cells are collected. From the thus collected cells, a T cell antigen receptor is efficiently obtained from the culture according to a customary method [see, for example, S. C. Meuer, J. Exp. Med., 157, 705 (1983)]. Illustratively stated, the cloned T cells are suspended in a PBS (a phosphate buffer containing 0.85 % NaCl, pH7.2) containing 1 % Toriton X-100. The resulting suspension is stirred on ice for 1 hour so that membrane proteins of the cloned T cell are dissolved in the suspension. Then, the suspension is subjected to affinity column chromatography using a column packed with Sepharose 4B (manufactured and sold by Pharmacia Fine Chemicals AB, Sweden) to which a monoclonal antibody against a T cell antigen receptor is bonded. The monoclonal antibody against a T cell antigen receptor may be prepared by a method as described in the later-mentioned Example 5.

Thus, there is obtained a T cell antigen receptor in substantially pure form.

The thus obtained T cell antigen receptor has a molecular weight of about 90,000 in terms of a value as measured by SDS-polyacrylamide gel electrophoresis

under a unreduced, condition. However, when the T cell antigen receptor is subjected to SDS-polyacrylamide gel electrophoresis under a reduced condition, there are found two bands on the gel, i.e., a band corresponding to a molecular weight of about 50,000 and a band corresponding to a molecular weight of about 45,000. This shows that the T cell antigen receptor is a heterodimer comprising a protein having a molecular weight of about 50,000 and, covalently bonded thereto through a disulfide bond, a protein having a molecular weight of about 45,000.

On the other hand, when the T cell antigen receptor is obtained from the cloned T cell of the present invention after the cloned T cell is treated with tunicamycin, the thus obtained T cell antigen receptor has a molecular weight of about 60,000 in terms of a value as measured by SDS-polyacrylamide gel electrophoresis under a non-reduction condition. Further, when the thus obtained T cell antigen receptor is subjected to SDS-polyacrylamide gel electrophoresis under a reduction condition, it is found that the T cell antigen receptor is a heterodimer comprising two proteins each having a molecular weight of about 30,000. These results show that the T

cell antigen receptor of the present invention is a heterodimer comprising two proteins each containing sugar. The above-mentioned molecular weights of the T cell antigen receptor are consistent with those of a T cell antigen receptor reported in J. Exp. Med., 158, 1547 (1983). The T cell antigen receptor of the present invention may or may not contain sugar.

The purity of the T cell antigen receptor of the present invention is about 95 % or more. The purity may be determined by subjecting the T cell antigen receptor to SDS-polyacrylamide gel electrophoresis, followed by densitometry using a densitometer model ADC-20EX (manufactured and sold by Kayagaki Co., Ltd., Japan).

The T cell antigen receptor of the present invention may also be produced by a customary recombinant DNA technique. Illustratively stated, mRNAs are obtained from a cloned T cell of the present invention which contains an intended T cell antigen receptor, and using the thus obtained mRNAs, cDNAs are synthesized. From the thus synthesized cDNA, a cDNA coding for the intended T cell antigen receptor is isolated by means of cloning. The thus isolated cDNA is ligated to an appropriate expression vector to obtain a recombinant DNA. With the recombinant DNA, cells of

E. coli, a yeast or an animal are transfected to obtain a transformant. The transformant is cultured in an appropriate medium, causing the transformant to produce the T cell antigen receptor.

5           The T cell antigen receptor of the present invention can bind to plural kinds of tumor cells as mentioned above with respect to the cloned T cell. The T cell antigen receptor is defined to be capable of binding to at least two kinds of tumor cells. Of  
10       course, the more kinds of tumor cells the T cell antigen receptor can bind, the better the T cell antigen receptor.

          In still a further aspect of the present invention, there is provided a T cell antigen receptor  
15       which is capable of binding to plural kinds of tumor cells and contains a marker bonded thereto.

          The marker-bonded T cell antigen receptor of the present invention may be obtained by bonding a marker to the T cell antigen receptor as mentioned before.  
20       As the marker, there may be mentioned, for example, fluorescent substances such as fluorescein isothiocyanate (FITC) and rodamine, enzymes such as peroxidase,  $\beta$ -galactosidase and glucose oxidase, radioisotopes such as  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{32}\text{S}$ ,  $^{14}\text{C}$  and  $^3\text{H}$ , etc.

The marker may be bonded to a T cell antigen receptor according to a customary method for obtaining a labeled antibody. As such a method, there may be mentioned, for example, a method in which FITC is bonded to a T cell antigen receptor under an alkaline condition, a method in which a maleimide group is introduced into an enzyme, and the resulting enzyme is bonded to a T cell antigen receptor through N-succinimidyl 3-(pyridyldithio)propionate (SPDP), a method in which an enzyme is bonded to an SH group of a T cell antigen receptor, a method in which a T cell antigen receptor is labeled with  $^{125}\text{I}$  by a customary lactoperoxidase method, and the like. However, the method for bonding a marker to a T cell antigen receptor varies depending upon the kind of the marker and, therefore, the method should not be limited to the above-mentioned methods.

The amount of the marker bonded to the T cell antigen receptor varies depending upon the kind of the marker. Generally, the marker may be bonded to the T cell antigen receptor in an amount of about 1 to about 10 moles/mole of the T cell antigen receptor.

In still a further aspect of the present invention, there is provided a T cell antigen receptor which is capable of binding to plural kinds of tumor



cells and contains a cytotoxin bonded thereto.

The cytotoxin-bonded T cell antigen receptor of the present invention may be obtained by bonding a cytotoxin to the T cell antigen receptor as mentioned before. As the cytotoxin, there may be mentioned, for example, anticancer drugs, biological toxic substances derived from plants, animal or the like, light-activated toxins, radioisotopes, etc. As the anti-cancer drugs, there may be mentioned, for example, alkyl reagents such as cyclophosphamide and nitrogen mustard, metabolic antagonists such as N<sup>4</sup>-behenoil ara-C, fluorouracil, 1-franocyl-5-fluorouracil and mercaptopurin, antibiotics such as bleomycin, mitomycin, actinomycin D and cycloheximide, hormones such as prednisone and prostaglandin, etc. As the biological toxic substances, there may be mentioned, for example, toxins such as snake toxin, diphtheria toxin and lysin. As the light-activated toxin, there may be mentioned, for example, hemaloporphyrin derivatives. As the radioisotopes, there may be mentioned, for example, <sup>125</sup>I, <sup>60</sup>Co, <sup>90</sup>Sr, <sup>32</sup>P, <sup>192</sup>Ir, etc.

The cytotoxin may be bonded to a T cell antigen receptor by a customary method. As the method for bonding a cytotoxin to a T cell antigen receptor,

there may be mentioned, for example, a method in which the lysin A chain of toxin of a bean is bonded to a T cell antigen receptor through N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) to form a complex, a method in which a T cell antigen receptor is bonded to a surface of a ribosome containing an anticancer agent such as actinomycin D, a method in which an anticancer agent such as adriamycin is bonded to a T cell antigen receptor using a dextran as a crosslinking agent to form a complex, and the like. However, the method for bonding a cytotoxin to a T cell antigen receptor varies depending upon the kinds of the cytotoxin and, therefore, the method should not be limited to the above-mentioned methods.

The amount of the cytotoxin bonded to the T cell antigen receptor varies depending upon the kind of the cytotoxin. Generally, the cytotoxin may be bonded to the T cell antigen receptor in an amount of about 1 to about 100 moles/mole of the T cell antigen receptor.

The cloned T cell of the present invention can recognized plural kinds of tumors due to the T cell antigen receptor held on the cloned T cell, which receptor can bind to plural kinds of tumors. The cloned t cell can be multiplied, as is different from natural T cells. Therefore, the cloned T cell of

the present invention is useful as a raw material for obtaining a T cell antigen receptor of the present invention. Especially, it is advantageous when the cloned T cell is a hybridoma, because the cloned T cell can be multiplied more easily than the cloned T cell which is not a hybridoma. The T cell antigen receptor of the present invention can specifically bind to plural kinds of tumors but does not bind to normal cells. Therefore, the T cell antigen receptor can be advantageously employed for clinical examination to determine whether a patient suffers from a tumor and for treatment of a tumor. Illustratively stated, when a marker is bonded to the T cell antigen receptor, the T cell antigen receptor can be advantageously used for identification and quantitative analysis of tumor antigen on a tumor cell membrane and cell-free tumor antigen. On the other hand, when a cytotoxin is bonded to the T cell antigen receptor, the T cell antigen receptor can be advantageously used for treatment of tumors such as gastric tumor, lung cancer, breast tumor, etc. The T cell antigen receptor of the present invention can also bind to virus antigen, bacterial antigen, MHC antigen, etc. Therefore, the T cell antigen receptor can also be

advantageously employed for the identification and quantitative analysis of such antigens and for the removal of malignant cells such as virus-infected cells and pathogenic cells in vivo.

5           In practicing the clinical examination using the marker-bonded T cell antigen receptor of the present invention, the amount of the marker-bonded T cell antigen receptor to be employed varies upon the kind of the marker. Generally, the marker-bonded T cell antigen receptor of the present invention may be  
10 employed in an amount of about 1 ng to 10 µg per sample (such as serum, tissues, etc.) to be examined.

          In practicing the treatment of tumors using the cytotoxin-bonded T cell antigen receptor of the  
15 present invention, the amount of the cytotoxin-bonded T cell antigen receptor to be administered varies depending upon the body weight, age, sex, etc. of a patient to be treated. Generally, the cytotoxin-bonded T cell antigen receptor may be administered to  
20 a patient in an amount of about 10 µg to about 1 mg/kg of the body weight of a patient.

          The present invention will now be described in detail by reference to the following Examples, which should not be construed to limit the scope of the  
25 present invention.

In the following Examples, tumor cells used for screening are publicly available from the facilities described in Protein, Nucleic Acid, Enzyme 23, 697 (1978), published by Kyoritsu Shuppan, Tokyo.

5           Of the cloned T cells of the present invention obtained in the following Examples, the following cloned T cells have been deposited at Public Health Laboratory Service Center for Applied Microbiology and Research (Porton Down, Salisbury Wiltshire, SP40JG, U.K.)

10

| <u>Cloned T cell</u> |           | <u>Deposit No.</u> |
|----------------------|-----------|--------------------|
| Human cloned T cell  | clone 51  | 85082201           |
| Human cloned T cell  | clone 5B5 | 86022601           |
| Human hybridoma      | H51-4-D1  | 85082202           |

Example 1

(Establishment of human cloned cytotoxic T cells which are capable of killing tumors)

5       The cloning of human T cells and screening of the cloned cytotoxic T cells capable of recognizing tumors were effected as follows.

10       First, human lymphocytes were obtained as follows. Human peripheral blood was collected from an adult man, diluted two-fold with Hank's solution (manufactured and sold by Nissui Pharmaceutical Co., Ltd., Japan), overlaid on Ficoll-Paque solution (manufactured and sold by Pharmacia Fine Chemicals AB, Sweden) and subjected to centrifugation at 2000 rpm for 20 min. Thus, there was obtained a mixture in the form of layers. The middle layer which is the lymphocyte layer was collected from the mixture, washed with Hank's solution, and then suspended at the concentration of  $2 \times 10^6$  cells/ml in RPMI 1640 medium (manufactured and sold by Nissui Pharmaceutical Co., Ltd., Japan) to which fetal bovine serum had been added in an amount of 10 (w/v) %. To the suspension was added a lectin PHA-P (Difco Laboratories, U.S.A.) to a concentration of 0.1 %, and the mixture was placed in a culture bottle and cultured at 37 °C for 25       48 hours in an air containing 5 % CO<sub>2</sub>. Thus, the

lymphocytes were activated by lectin (PHA-P), and various cytoxic T cells and helper T cells which can recognize various human tumor cell lines were induced. In order to obtain a cloned cell of each activated lymphocyte, the activated lymphocytes were subjected to cloning according to the method of Kaieda [T. Kaieda, Meneki Jikken Sosa-ho (Experimental methods in Immunology) XI, p.689, edited by Japanese Society of Immunology]. illustratively stated, the activated lymphocytes were suspended at the concentration of 5 cells/ml in RPMI 1640 medium containing 20 v/v% fetal bovine serum and interleukin 2 (manufactured and sold by Boelinger-Manheim Co., Ltd., West Germany). To the resulting suspension were added self-lymphocytes treated with a solution containing 100 µg/ml of Mitomycin-C (manufactured and sold by Kyowa Hakko Kogyo Co., Ltd., Japan) at 37 °C for 45 min so that at the self-lymphocyte concentration became  $1 \times 10^5$  cells/ml. The resulting mixture was put into each well of 96 well plate (Falcon No. 3072 manufactured and sold by Falcon, U.S.A.) in an amount of 200 µl and cultured in an air containing 5 % CO<sub>2</sub> at 37 °C for 2 weeks to form cloned T cells. Whether these cloned T cells recognize tumor cells was deter-

mined through evaluation of the cytotoxicity of the cloned T cells against tumor cells. The evaluation of the cytotoxicity is as follows. First, various tumor cells were labeled using  $^{51}\text{Cr}$  according to a customary method [R.M. Thorn et al, J. Immunol Methods 4, 301 (1974)], and  $1 \times 10^4$  cells of the labeled tumor cell and  $1 \times 10^5$  cells of each cloned T cell were mixed and cultured in 200  $\mu\text{l}$  of RPMI medium containing 5 v/v% fetal bovine serum (in an air containing 5 %  $\text{CO}_2$  at 37 °C). Then, by counting the radioactivity of  $^{51}\text{Cr}$  released in the supernatant of the cultured mixture, the cytotoxicity of the cloned T cells was evaluated.

The cytotoxicity was calculated according to the following formula.

$$\text{Cytotoxicity (\%)} = [(B-C)/(A-C)] \times 100$$

(wherein A is the radioactivity of  $1 \times 10^4$  cells of the  $^{51}\text{Cr}$ -labeled tumor cell, B is the radioactivity in the supernatant of the cultured mixture in which  $1 \times 10^4$  cells of the  $^{51}\text{Cr}$ -labeled tumor cells and  $1 \times 10^5$  cells of the cloned T cell were cultured, and C is the radioactivity in the supernatant of a medium in which only  $1 \times 10^4$  cells of  $^{51}\text{Cr}$ -labeled tumor cell were cultured.)

The cloned T cell of which the cytotoxicity against a tumor cell was 10 % or more was regarded as



being capable of recognizing the tumor cell.

10,000 cells were subjected to cloning under the conditions as described above. As a result, about 500 kinds of cloned T cells were obtained. Of them, about 5 100 kinds of the cells exhibited cytotoxicity against at least one kind of the human tumor cell lines (cloned human cytotoxic T cells). The above-mentioned cloning procedures were repeated to obtain 21 cloned human cytotoxic T cells capable of killing at least 10 two kinds of tumor cell lines (Nos. 4, 8, 15, 19, 24, 28, 36, 49, 51, 75, 83, 90, 95, 115, 131, 138, 150, 165, 172, 188 and 5B5). The cytotoxicities of the thus obtained clones against various tumor cells and fibroblasts derived from a fetus are shown in Tables 1 15 and 2. These clones required interleukin 2 for their growth. Therefore, the clones were cultured in RPMI 1640 medium containing 20 v/v% fetal bovine serum and interleukin 2. Every 7 to 10 days, the PHA-P and human self peripheral blood lymphocytes from which the 20 clones were derived were treated with mitomycin and added to the culture of the clones. The clones were capable of multiplying even after the clones were cultured for 6 months. Through the repetition of the above-mentioned procedures, it was affirmed that the

0203403

cloned human T cells were obtained with high reproducibility.

0203403

Table 1

Cytotoxicity of cloned human cytotoxic T cells  
against various tumor cells

|                                 |                  |         | Cytotoxicity of<br>cloned human cytotoxic T cells |   |    |    |    |    |    |    |    |    |    |
|---------------------------------|------------------|---------|---|---|----|----|----|----|----|----|----|----|----|
|                                 |                  |         | clones  |   |    |    |    |    |    |    |    |    |    |
|                                 |                  |         | 4   | 8 | 15 | 19 | 24 | 28 | 36 | 49 | 51 | 75 | 83 |
| human<br>tumor<br>cell<br>lines | gastric<br>tumor | MKN-1   |   |   |    |    |    |    |    |    | +  | +  | +  |
|                                 |                  | KATOIII | -   | + | -  | -  | -  | -  | -  | -  | +  | +  | +  |
|                                 |                  | PC-1    |   |   |    | +  |    |    |    |    | -  |    |    |
|                                 | lung<br>tumor    | PC-9    | -   | - | -  | -  | -  | -  | -  | -  | -  | +  | +  |
|                                 |                  | PC-10   |   |   |    | +  |    |    |    |    | +  | +  | +  |
|                                 |                  | PC-13   | -   | - | -  | +  | -  | -  | -  | -  | +  | +  |    |
|                                 |                  | PC-14   |   |   |    | +  |    |    |    |    | +  | +  | +  |
|                                 | colon<br>tumor   | C-1     | +   | - | -  | -  | -  | -  | -  | -  | -  | +  |    |
|                                 |                  | M7609   | +   |   |    |    |    |    |    |    |    |    |    |
|                                 | rectal<br>tumor  | CaR-1   | -   | - | +  | -  | -  | -  | -  | -  |    |    |    |
|                                 |                  | S-7512  |   |   | +  |    |    |    |    |    |    |    |    |
|                                 | cystic<br>tumor  | H-1     |   |   |    |    |    |    |    |    | -  | +  | +  |
|                                 | hepatoma         | HLE     | -   | - | -  | -  | +  | -  | -  | -  | -  |    |    |
|                                 |                  | HLF     |   |   |    |    | +  |    |    |    |    |    |    |
|                                 | bladder<br>tumor | NBT-2   |   |   |    |    |    |    |    | +  | +  | +  | +  |
|                                 |                  | KU-1    |   |   |    |    |    |    |    | +  |    |    |    |
|                                 | throat<br>tumor  | KB      |   |   |    |    |    |    |    |    | +  | +  | +  |
|                                 | kidney<br>tumor  | W-2     | -   | - | -  | -  | -  | +  | -  | -  | -  | +  |    |
|                                 |                  | NRC-12  |   |   |    |    |    | +  |    |    |    |    |    |
|                                 | breast<br>tumor  | HBC-4   | -   | - | -  | -  | -  | -  | +  | -  |    |    |    |
|                                 |                  | HBC-6   |   |   |    |    |    |    | +  |    |    |    |    |
|                                 | uterine<br>tumor | HeLa    |   |   |    |    |    |    |    |    | +  | +  | +  |
|                                 | melanoma         | HMV-1   | -   | - | -  | -  | -  | -  | -  | -  | +  | +  | +  |
|                                 |                  | HMV-2   |   |   |    |    |    |    |    |    | +  |    |    |
| fetal<br>cells                  | tongue           | HET     |   |   |    | -  |    |    |    |    | +  | +  | -  |
|                                 | lung             | HEL     |   | - |    |    |    |    |    |    | -  | -  | -  |
|                                 | foreskin         | MRHF    |   |   |    |    |    |    |    |    | -  | -  | -  |
| normal lymphocytes              |                  |         | -   | - | -  | -  | -  | -  | -  | -  | -  | -  | -  |

cytotoxicity: - (less than 10%), + (10% or more)

0203403

Table 2

Cytotoxicity of cloned human cytotoxic T cells  
against various target cells

|                    |          | Cytotoxicity of<br>cloned human cytotoxic T cells |    |     |     |     |     |     |     |     |     |
|--------------------|----------|---|----|-----|-----|-----|-----|-----|-----|-----|-----|
|                    |          | clones  |    |     |     |     |     |     |     |     |     |
|                    |          | 90  | 95 | 115 | 131 | 138 | 150 | 165 | 172 | 188 | 5B5 |
| gastric            | MKN-1    | +   | +  | -   | -   | -   | -   | -   | +   | -   | +   |
| tumor              | KATO-III | +   | -  | -   | -   | +   | -   | -   | +   | -   |     |
|                    | PC-9     | -   | -  | -   | -   | -   | -   | -   | +   | -   |     |
| lung               | PC-10    | -   | -  | +   | -   | -   | -   | -   | +   | -   | +   |
| tumor              | PC-13    |   |    | +   |     |     |     |     |     |     | +   |
|                    | PC-14    |   |    | +   |     |     |     |     |     |     |     |
| colon              | C-1      | +   | +  | -   | -   | -   | +   | -   | +   | -   |     |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| cystic             | H-1      | +   | -  | -   | -   | -   | -   | -   | +   | -   |     |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| bladder            | NBT-2    | +   | -  | -   | +   | -   | -   | +   | +   | +   | +   |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| throat             | KB       | -   | +  | -   | +   | +   | +   | -   | +   | -   | +   |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| kidney             | W-2      |   |    |     |     |     |     | +   | +   | +   |     |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| uterine            | HeLa     | -   | -  | -   | +   | +   | +   | +   | +   | -   |     |
| tumor              |          |   |    |     |     |     |     |     |     |     |     |
| melanoma           | HMV-1    | -   | -  | -   | -   | -   | -   | -   | +   | -   |     |
| normal lymphocytes |          | -   | -  | -   | -   | -   | -   | -   | -   | -   | -   |

cytotoxicity: - (less than 10%), + (10% or more)

Example 2

(Establishment of tumor cell recognizing cloned human helper T cells which are capable of recognizing tumors)

5           Cloned human helper T cells capable of recognizing tumors were obtained as follows. Human lymphocytes were collected, activated by a lectin and cloned in substantially the same manner as in Example 1 to obtain 100 kinds of cloned T cells. The thus obtained  
10           cloned T cells were subjected to assay for determining the helper activity. The assay was effected as follows. First,  $1 \times 10^6$  cells of each cloned T cell were suspended in 1 ml of an RPMI medium containing 10 v/v% fetal bovine serum. Then, to the resulting  
15           suspension were added  $1 \times 10^5$  cells of self lymphocytes treated with mytomycin and  $5 \times 10^5$  cells of tumor cells treated with mytomycin. The resulting mixture was cultured in an air containing 5 % CO<sub>2</sub> at 37 °C for 40 hours. After culturing, the activity of  
20           interleukin 2 in the supernatant of the culture medium was measured by a customary method [S. Gillis et al; J. Immunol. 120, 2027 (1978)], and the helper activity was calculated based on the activity of interleukin 2 by the following formula.

25           Helper activity = (B/A) - 1

wherein

A: Activity of interleukin 2 in the supernatant of the culture medium in which the mytomycin-treated self lymphocytes and tumor cells were cultured

B: Activity of interleukin 2 in the supernatant of the culture medium in which the cloned T cells, mytomycin-treated self lymphocytes and tumor cells were cultured.

The clone of which the helper activity against a tumor cell was 1 or more was regarded as being capable of recognizing the tumor.

As a result, it was found that of the 100 kinds of cloned T cells, 5 kinds of clones (Nos. 8, 32, 55, 63 and 78) had a helper activity of 1 or more against at least two kinds of tumor cells (cloned human helper T cells).

The helper activities of the 5 kinds of cloned helper T cells are shown in Table 3.

Through the repetition of the above-mentioned procedures, it was affirmed that the clones were obtained with high reproducibility. The clones were capable of multiplying even after the clones were cultured for 6 months.

Table 3

Ability of cloned human helper T cells  
to recognize various tumor cells and  
normal cells

|                                 |          |         | Helper activity of cloned human helper<br>T cells |    |    |    |    |
|---------------------------------|----------|---------|---|----|----|----|----|
|                                 |          |         | clones  |    |    |    |    |
|                                 |          |         | 8   | 32 | 55 | 63 | 78 |
| human<br>tumor<br>cell<br>lines | lung     | PC-10   | +   | -  | +  | -  | -  |
|                                 | tumor    | PC-13   | +   | -  | +  | -  | -  |
|                                 |          | PC-14   | +   | -  | +  | -  | -  |
|                                 | gastric  | MKN-1   | -   | -  | +  | +  | +  |
|                                 | tumor    | KATOIII | -   | -  | +  | +  | +  |
|                                 | colon    | C-1     | -   | +  | +  | +  | -  |
|                                 | tumor    |         |   |    |    |    |    |
|                                 | throat   | KB      | -   | -  | -  | -  | -  |
|                                 | tumor    |         |   |    |    |    |    |
|                                 | bladder  | NBT-2   | -   | -  | -  | -  | -  |
|                                 | tumor    |         |   |    |    |    |    |
|                                 | cystic   | H-1     | -   | +  | +  | -  | -  |
|                                 | tumor    |         |   |    |    |    |    |
| normal lymphocytes              | kidney   | W-2     | -   | -  | -  | -  | -  |
|                                 | tumor    |         |   |    |    |    |    |
|                                 | uterine  | HeLa    | -   | -  | -  | -  | -  |
|                                 | tumor    |         |   |    |    |    |    |
|                                 | melanoma | HMV-1   | -   | -  | -  | -  | -  |
| normal lymphocytes              |          |         | -   | -  | -  | -  | -  |

Helper activity: - (less than 1), + (1 or more)

Example 3

(Establishment of cloned murine cytotoxic T cells which are capable of killing tumors)

5        Cloned murine cytotoxic T cells capable of recognizing tumor cells were obtained as follows.

      Spleen cells of a BALB/c mouse were obtained according to the following procedures. First, a BALB/c mouse was killed, and the spleen was taken out from the mouse. Then, the cells of the spleen were  
10        suspended in 10 ml of a Hank's solution contained in Petri dish. The obtained cell suspension was put into a test tube and allowed to stand still for 3 min to cause the tissue fragments to precipitate. The precipitated tissue fragments were removed. Then, the  
15        cell suspension was transferred to another test tube and subjected to centrifugation to separate the suspension into precipitates and a supernatant. After removing the supernatant, 2 ml of 0.85 % aqueous solution of ammonium chloride was added to the pre-  
20        cipitates to obtain a suspension. The suspension was kept at 37 °C for 2 min to effect the lysis of the red blood cells contained in the suspension. The suspension was then subjected to centrifugation to separate the suspension into cells and a supernatant. The  
25        supernatant thus formed was removed. Then, an RPMI



1640 medium containing 10 v/v% fetal bovine serum was added to the cells in such an amount that the resulting suspension had the cell concentration of  $2 \times 10^6$  cells/ml.

5           10 ml of the thus obtained murine spleen cell suspension was put in a culture bottle. After adding 50 µg of Con A (manufactured and sold by E.Y. Laboratories Inc., U.S.A.) to the suspension, the mixture was incubated for 40 hours. The lymphocytes activated  
10 by a lectin were cloned in substantially the same manner as in Example 1 except that a rat-derived interleukin 2 (manufactured and sold by Coraborative Inc., U.S.A.) was used instead of the interleukin 2 and that BALB/c spleen cells treated with mytomycin  
15 were used instread of the human self lymphocytes.

          The cytotoxicities of the obtained cloned murine T cells against tumor cells were measured in substantially the same manner as in Example 1. The cloned T cell of which the cytotoxicity against a tumor cell  
20 was 10 % or more was regarded as being capable of recognizing the tumor cell. As a result, it was found that cloned cytotoxic T cells (Nos. 3, 12, 23, 41 and 58) were capable of recognizing tumor cells. The results are shown in Table 4.

Table 4

Cytotoxicity of cloned murine cytotoxic T cells  
against various tumor cells

|                                 |          |         | Cytotoxicity of<br>cloned murine cytotoxic T cells |    |    |    |    |
|---------------------------------|----------|---------|--|----|----|----|----|
|                                 |          |         | clones   |    |    |    |    |
|                                 |          |         | 3  | 12 | 23 | 41 | 58 |
| human<br>tumor<br>cell<br>lines | lung     | PC-10   | -  | +  | -  | +  | +  |
|                                 | tumor    | PC-14   | -  | +  | -  | +  | +  |
|                                 | gastric  | MKN-1   | -  | -  | +  | +  | +  |
|                                 | tumor    | KATOIII | -  | -  | +  | +  | +  |
|                                 | throat   | KB      | -  | -  | -  | -  | +  |
|                                 | tumor    |         |  |    |    |    |    |
|                                 | bladder  | NBT-2   | +  | -  | -  | -  | +  |
|                                 | tumor    |         |  |    |    |    |    |
|                                 | kidney   | W-2     | -  | -  | -  | -  | +  |
|                                 | tumor    |         |  |    |    |    |    |
|                                 | uterine  | HeLa    | -  | -  | -  | -  | +  |
|                                 | tumor    |         |  |    |    |    |    |
|                                 | melanoma | HMV-1   | -  | -  | -  | -  | +  |
| normal lymphocytes              |          |         | -  | -  | -  | -  | -  |

cytotoxicity: - (less than 10%), + (10% or more)

Example 4

(Preparation of a hybridoma derived from the clone 51)

The cell line CEM-AG<sup>R</sup> was used as the 8-  
5 azaguanine resistant human T-lymphoma. The cell line  
CEM-AG<sup>R</sup> was prepared according to the method described  
in Japanese Patent Application Laid-Open Specification  
No. 57-206383. The cells of the cell line were sus-  
pended in an RPMI 1640 medium containing 20 v/v % FCS  
10 and 100  $\mu$ M of 8-azaguanine. The resulting suspension  
was cultured for 2 days while the medium was changed  
to a fresh medium every day by the method in which the  
culture was subjected to centrifugation to separate  
the culture into cells and a supernatant, and after  
15 the supernatant was discarded, to the cells was added  
a fresh medium. The cells multiplied actively. Then,  
the cells were collected by centrifugation. The col-  
lected cells were suspended in an RPMI 1640 medium  
containing 20 v/v % FCS and allowed to stand for one  
20 day.  $6 \times 10^7$  cells of the above-obtained cell line  
CEM-AG<sup>R</sup> and  $8 \times 10^5$  cells of the human cytotoxic T  
cell 51 obtained in Example 1 which was capable of  
recognizing a wide variety of tumor cells were sub-  
jected to cell fusion. That is, both the above-  
25 mentioned cells were washed three times with a MEM

medium not containing FCS which had been preheated to 37 °C, and suspended in the MEM medium. Then, the cell suspension was put in a 50 ml conical tube, mixed sufficiently and centrifuged at 800 rpm at room temperature for 10 min to separate the suspension into a cell pellet and a supernatant. After removing the supernatant, the resulting cell pellet was shaken gently. To the cell pellet was added 0.5 ml of a MEM solution containing 45 w/v % of PEG-6000 (manufactured and sold by Kochlight, England), which solution had been heated to 37 °C. The resulting mixture was shaken sufficiently for 30 seconds, and allowed to stand in a CO<sub>2</sub> gas incubator filled with a gas containing 5 % CO<sub>2</sub> and 95 % air at 37 °C for 6 min. Then, 12 ml of a MEM medium (preheated at 37 °C) not containing FCS was added to the mixture at a rate of 2 ml per minute while the conical tube was rotated. Then, 25 ml of a MEM medium was rapidly added to the mixture. The mixture was centrifuged at 800 rpm at room temperature for 10 min to separate the mixture into a cell pellet and a supernatant, and the supernatant was removed. The obtained pellet was loosened. Then, 120 ml of an RPMI 1640 medium containing 30 v/v% FCS (preheated to 37 °C) was gently added to the

loosened pellet to give a suspension having a CEM-AG<sup>R</sup> cell concentration of  $5 \times 10^5$  cells/ml. 1 ml of the thus obtained suspension was put in each of 120 wells of five 24 well culture plates (Costar No. 3524, manufactured and sold by Costar, U.S.A.). 24 hours later, 1 ml of HAT medium [an RPMI 1640 medium containing  $1 \times 10^{-4}$  M hypoxanthine (manufactured and sold by Sigma Chemical Company, U.S.A.),  $2 \times 10^{-7}$  M aminopterin (manufactured and sold by Sigma Chemical Company, U.S.A.),  $1.6 \times 10^{-5}$  M thymidine (manufactured and sold by Sigma Chemical Company, U.S.A.) and 20 v/v % FCS] was added to each well. Half of the supernatant of the culture medium in each well was removed and 1 ml of a fresh HAT medium was added to each well every two days and the culturing was effected in a 5 % CO<sub>2</sub> gas incubator at 37 °C for 3 weeks. The cell lines thus multiplied were then put in a HT medium (the same medium as the HAT medium except that aminopterin is not contained) and further cultured for 1 week. The cell lines were then transferred into a normal medium (an RPMI 1640 medium containing 20 v/v % FCS but not containing HAT). As a result, 6 kinds of hybridomas were obtained. The hybridomas thus obtained were subjected to assay to determine whether or not the obtained hybridomas had produced T cell antigen

receptors. The assay was effected by staining the hybridomas according to the so-called indirect method using anti-T cell antigen receptors as a first antibody and FITC labeled murine Ig antibody (manufactured and sold by TAGO Inc., U.S.A.) as a second antibody. The thus stained hybridomas were examined by fluorescence microscopy. As a result, it was found that among the 6 kinds of clones of hybridomas, only 1 kind of clone had a ring-shaped stained portion. The results show that only one kind of clone had produced a T cell antigen receptor. This clone was named H51-4. On the other hand, the parent cell line CEM-AG<sup>R</sup> was not stained at all by this assay method. The clone H51-4 contained both of cells which had a clearly stained portion, that is, had a large amount of a T cell antigen receptor, and cells which were stained a little, that is, had a small amount of a T cell antigen receptor. Therefore, in order to obtain a hybridoma capable of producing a large amount of a T cell antigen receptor, subclones of the clone H51-4 were obtained by effecting cloning according to a customary method as follows. First,  $1 \times 10^7$  cells of the cell line CEM-AG<sup>R</sup> were washed with a customary growth medium and suspended in 60 ml of the HAT

medium. Then, both the cells of the clone H51-4 were  
suspended in the medium at a concentration of 2.5  
cells/ml, and added to the above-mentioned HAT medium.  
0.2 ml of the resulting mixture was put in each well  
5 of a 96 well microplate having a capacity of  
200  $\mu$ l/well (Falcon No. 3072, manufactured and sold by  
Falcon, U.S.A.). Every two weeks, half of the super-  
natant of the mixture in each well was removed and a  
fresh HAT medium preheated to 37 °C was added to each  
10 well to keep the above-mentioned cells multiplying.  
Thus, there were obtained subclones of the clone H51-  
4. The cells of the thus obtained subclones were  
subjected to staining by the above-mentioned indirect  
method to select from the above-obtained subclones the  
15 subclones, almost all the cells of which had a clearly  
stained portion. As a result, there were selected two-  
subclones. The thus selected subclones produced a T  
cell antigen receptor in large amount very stably.  
The selected subclones were named H51-4-A2 and H51-4-  
20 D1.

Example 5

(Culturing of cloned human cytotoxic T cells,  
 $^{131}\text{I}$  labeling of membrane proteins of the cells and  
preparation of soluble membrane protein fraction of  
the cells)

The human cytotoxic T cell clone 51 obtained in  
Example 1 was cultured in the presence of interleukin  
2 to obtain  $2 \times 10^9$  cells. From the cells, T cell  
antigen receptors were obtained as follows. The cells  
were washed three times with Hank's solution, sus-  
pended in 2 ml of PBS (containing 1 mM phenyl methyl  
sulfonyl fluoride, 1 mM EDTA and 10 mM NaF; pH 7.2)  
containing 1 % Triton X-100 and stirred in ice for 1  
hour so that the membrane proteins of the cells were  
made soluble. The mixture was subjected to centri-  
fugation at 10000 g for 20 min to remove the debris of  
the cells from the mixture. Thus, there was obtained a  
soluble membrane protein fraction.

(Preparation of anti-T cell antigen receptor  
monoclonal antibody)

An anti-T cell antigen receptor monoclonal anti-  
body was obtained as follows. First,  $1 \times 10^8$  cells of  
human peripheral blood lymphocytes were suspended in  
100 ml of an RPMI medium (containing 0.1 % PHA-P)  
containing 10 v/v% fetal bovine serum and cultured for



two days. Then, the multiplication of the cells were effected in a medium containing interleukin 2 to obtain  $1 \times 10^9$  cells of activated T cells. The obtained cells were treated in substantially the same manner as mentioned before to obtain a soluble membrane protein fraction of the cells. The fraction was then placed on Sephacryl S-200 (manufactured and sold by Pharmacia Fine Chemicals AB, Sweden) and subjected to gel chromatography using PBS as an eluent to collect fractions having molecular weights of 70,000 to 100,000, respectively. The fractions were put together and concentrated to a volume of 0.5 ml. The thus obtained concentrate was mixed with an equivolume of Freund's complete adjuvant. The resulting mixture was injected to a BALB/c mouse. 10 days later and 20 days later, 100  $\mu$ l of the above-obtained concentrate was twice injected to the mouse intraperitoneally. 10 days after the last injection of the concentrate, 100  $\mu$ l of the concentrate was injected to the mouse intravenously to complete the immunization of the mouse. 3 days after the intravenous injection, the spleen cells of the immunized mouse was taken out and fused with murine myeloma P3U1 by a customary method [G. Kohler & C. Milstein; Nature 256, 49 (1975)],

thereby to obtain hybridomas. The hybridomas were subjected to screening with respect to the binding activity, to human T cells, of a supernatant obtained from the culture of the hybridoma and with respect to the presence of antibody in the supernatant, which antibody was able to binding to a peptide of human T cell antigen receptor  $\beta$  constant region which had been organo-chemically synthesized according to a customary solid phase method based on the amino acid sequence of a T cell antigen receptor described in Nature, 308, 145 (1984). Thus, there was obtained a hybridoma producing anti-T cell antigen receptor antibody. The supernatant of the hybridoma was subjected to immunoprecipitation with the T cell membrane protein fraction as obtained before and subjected to SDS-polyacrylamide gel electrophoresis. As a result, the precipitates were formed and there were observed a band corresponding to the molecular weight of 90,000 under an unreduced condition, and two bands corresponding to molecular weights of 50,000 and 45,000 under a reduced condition. Thus, it was affirmed that the obtained hybridoma produced anti-T cell antigen receptor monoclonal antibody. The hybridoma was named 116-23.

(Preparation of anti-T cell antigen receptor

monoclonal antibody-bonded Sepharose 4B)

The hybridoma (116-23) was cultured in 1 l of an RPMI medium containing 20 v/v% fetal bovine serum. The culture was subjected to purification by a customary method by means of affinity chromatography using a Protein A-agarose column [T. Iwasaki, "Monoclonal antibody", published by Kodansha, Tokyo, p 175-177 (1983)], thereby to obtain 10 mg of anti-T cell antigen receptor monoclonal antibody. 1 mg of the obtained antibody was bonded to 2 g of CNBr-activated Sepharose 4B (manufactured and sold by Pharmacia Fine Chemicals AB, Sweden) as follows. First, 1 g of CNBr-activated Sepharose 4B was sufficiently washed with 1 mM (200 ml) HCl on a glass filter (G3), further washed with 200 ml of a coupling buffer (0.1 M NaHCO<sub>3</sub>-Na<sub>2</sub>CO<sub>3</sub> buffer, pH 8.3, 0.5 M NaCl) and dried. Then, the antibody was dissolved in the coupling buffer in such an amount that the resulting solution had the antibody concentration of 1 mg/ml. To 4 ml of the thus obtained solution was added the dried Sepharose, and the mixture was reacted at room temperature for 2 hours while gently stirring. 2 hours later, 5 ml of 0.2 M glycine (pH 8.0) was added to the reaction mixture, and the resulting mix-

ture was reacted at room temperature for 2 hours to block excess active groups. The obtained mixture was placed on a glass filter (G3) and washed successively with 200 ml of the coupling buffer, 200 ml of an acetate buffer (0.1 M sodium acetate, pH 4, 0.5 M NaCl) and 200 ml of a phosphate buffer (pH 7.0, 0.15 M NaCl) to obtain antibody-bonded Sepharose.

(Purification of T cell antigen receptor by affinity chromatography)

The above-obtained soluble membrane protein fraction of the human cytotoxic T cell clone 51 was put into a column packed with 3 ml of anti-T cell antigen receptor monoclonal antibody-bonded Sepharose 4B to cause the T cell antigen receptor to be adsorbed. Then, 200 ml of the PBS was flowed through the column to elute impurities. Subsequently, 10 ml of 0.1 M glycine-hydrochloric acid (pH 3.0) was added to the column to elute the adsorbed T cell antigen receptor. The eluate was neutralized and then concentrated to obtain 0.5 ml of a concentrate. The concentrate was subjected to SDS-polyacrylamide electrophoresis. As a result, there were detected a band corresponding to the molecular weight of about 90,000 under an unreduced condition. Further, there were detected two bands corresponding to the molecular weights of about

50,000 and about 45,000 under a reduced condition. Thus, it was affirmed that the clone 51 produced T cell antigen receptor.

(labeling with FITC of T cell antigen receptor)

5           The above-obtained concentrate containing 1  $\mu$ g of the T cell antigen receptor was subjected to dialysis against a phosphate buffer (10 mM sodium phosphate, 0.85 % NaCl, pH 7.2) to obtain 1 ml of the T cell antigen receptor solution. 1 ml of the T cell antigen  
10 receptor solution, 0.1 ml of 0.5 M carbonic acid-bicarbonate buffer (pH 9.3) and 10  $\mu$ l of 4  $\mu$ g/ml FITC solution (manufactured and sold by Sigma Chemical Company, U.S.A.) were put in a small beaker and reacted at room temperature for 6 hours. After the  
15 reaction, the mixture was dialyzed against a phosphate buffer, and 1 ml of a dialysate was stored at -20 °C.

(Binding activity of FITC-labeled T cell antigen receptor to tumor cells)

20           0.1 ml of the thus obtained FITC-labeled T cell antigen receptor derived from the clone 51 was mixed with an RPMI 1640 medium containing 5 v/v% fetal bovine serum and, suspended therein, various tumor cell lines recognized by the clone 51 (MKN-7, KATO-III, PC-10, NBT-2) at a concentration of  $1 \times 10^6$

cells/ml. The mixture was kept at 0 °C for 1 hour. Then, the mixture was washed with Hank's solution and observed under a fluorescence microscope. As a result, it was observed that these tumor cell lines emitted fluorescence of a ring shape. On the other hand, the cells which were not recognized by the clone 51 did not emit fluorescence. Thus, it was affirmed that the T cell antigen receptor acted as a tumor cell recognizing substance.

#### Example 6

A T cell antigen receptor was obtained from the human cytotoxic T cell clone 8 obtained in Example 1 in substantially the same manner as in Example 5 and the binding activity thereof to tumor cells was investigated. As a result, it was found that the receptor bound to MKN-1 and KATO-III, but not to the tumor cells which were not recognized by the clone 8.

#### Example 7

A T cell antigen receptor was obtained from the human cytotoxic T cell clone 19 obtained in Example 1 in substantially the same manner as in Example 5 and the binding activity thereof to tumor cells was investigated. As a result, it was found that the

receptor bound to PC-1, PC-10, PC-13 and PC-14, but not to the tumor cells which were not recognized by the clone 19.

5

Example 8

A T cell antigen receptor was obtained from the human cytotoxic T cell clone 24 obtained in Example 1 in substantially the same manner as in Example 5 and the binding activity thereof to tumor cells was  
10 investigated. As a result, it was found that the receptor bound to HLE and HLF, but not to the tumor cells which were not recognized by the clone 24.

Example 9

15

A T cell antigen receptor was obtained from the human cytotoxic T cell clone 36 as described in Example 1 in substantially the same manner as in Example 5 and the binding activity thereof to tumor cells was investigated. As a result, it was found  
20 that the receptor bound to HBC-4 and HBC-6, but not to the tumor cells which were not recognized by the clone 36.

Example 10

A T cell antigen receptor was obtained from the clone 51 derived hybridoma H51-4-D1 obtained in Example 4 in substantially the same manner as in Example 5 and the binding activity thereof to tumor cells was investigated. As a result, it was found that the receptor bound to MKN-1, KATO-III, PC-10 and NBT-2, but not to the tumor cells which were not recognized by the clone 51.

Example 11

A T cell antigen receptor was prepared from the clone 51 in substantially the same manner as in Example 1. The T cell antigen receptor was  $^{125}\text{I}$ -labeled by the lactoperoxidase method. First, to 100  $\mu\text{l}$  of 10  $\mu\text{g}/\text{ml}$  T cell antigen receptor solution in 0.05 M phosphate buffer (pH 7.5) were added 0.1 mCi of  $^{125}\text{I}$  (manufactured and sold by New England Nuclear Inc., England), 10  $\mu\text{l}$  of 0.2 mg/ml lactoperoxidase solution (manufactured and sold by Calbiochem Inc., U.S.A.; dissolved in a phosphate buffer) and 10  $\mu\text{l}$  of 0.2 mg/ml glucose oxidase solution (manufactured and sold by Calbiochem Inc., U.S.A.). Then, 2  $\mu\text{l}$  of 1 M glucose was added to the mixture to start a reaction. The reaction was effected at room temperature for



30 min. Subsequently, 15  $\mu$ l of 0.1 M sodium nitride was added to the reaction mixture to stop the reaction. The mixture was dialyzed successively against 0.05 M phosphate buffer containing 0.01 % sodium nitride and against 0.05 M phosphate buffer to obtain  $^{125}\text{I}$ -labeled T cell antigen receptor solution. The thus obtained solution was stored at  $-20\text{ }^{\circ}\text{C}$  (0.2 ml; specific activity, 100,000 cpm/ $\mu$ g).

15  $\mu$ l (6000 cpm) of the thus prepared  $^{125}\text{I}$ -labeled T cell antigen receptor solution was mixed with 0.2 ml of an RPMI 1640 medium containing 5 v/v% fetal bovine serum and various tumor cell lines (MKN-1, KATO-III, PC-10 and NBT-2) which tumor cell lines were recognized by the clone 51 suspended in the serum ( $1 \times 10^7$  cells/ml), and kept at  $0\text{ }^{\circ}\text{C}$  for 1 hour. Then, the mixture was washed with Hank's solution and subjected to the measurement of the radioactivity. As a result, it was found that the radioactivities of MKN-1, KATO-III, PC-10 and NBT-2 were 3800 cpm, 3600 cpm, 2900 cpm and 3900 cpm, respectively. This result shows that the tumor cell antigen on each tumor cell membrane can be determined by the marker-bonded T cell antigen receptor.

Example 12

A cell-free tumor antigen was determined by T cell antigen receptor as follows.

(Separation of membrane protein from tumor cell

5 NBT-2)

The tumor cell line NBT-2 which was recognized by the clone 51 were cultured in an amount of  $1 \times 10^{10}$  cells. The culture was subjected to treatment in substantially the same manner as in Example 1 so that the membrane proteins of the cultured cells were dissolved in the culture medium. The supernatant of the culture was obtained by centrifugation and subjected to dialysis against 10 mM phosphate buffer (pH 7.2, 0.85 % NaCl) to obtain 10 ml of a soluble membrane protein fraction.

15

(Preparation of antiserum against NBT-2 tumor cell membrane protein)

1 ml of the above-obtained NBT-2 membrane protein fraction and 1 ml of Freund's complete adjuvant were mixed to prepare an emulsion. The emulsion was injected to a BALB/c mouse three times at intervals of one week to effect immunization of the mouse. 3 days after the last injection, a blood sample was collected from the heart of the mouse and allowed to stand still, so that the sample separated into a clotted

25

substance and an antiserum. The antiserum was collected. From the sample, there was obtained 2 ml of an antiserum.

(Purification of antiserum by affinity  
5 chromalography)

2 ml of the NBT-2 tumor cell membrane protein fraction was reacted with 5 ml of CNBr-activated Sepharose (manufactured and sold by Pharmacia Fine Chemicals AB, Sweden) to prepare a membrane protein  
10 (antibody)-bonded Sepharose. The reaction was effected as follows.

First, 1 g of CNBr-activated Sepharose 4B was sufficiently washed with 1 mM (200 ml) HCl on a glass filter (G3), further washed with 200 ml of a coupling  
15 buffer (0.1 M Na HCO<sub>3</sub> buffer, pH 8.3, 0.5 M NaCl) and dried. Then, the antibody was dissolved in the coupling buffer in such an amount that the resulting solution had an antibody concentration of 1 mg/ml. To  
20 4 ml of the thus obtained solution was added the dried Sepharose and the mixture was reacted at room temperature for 2 hours while gently stirring. 2 hours later, 5 ml of 0.2 M glycine (pH 8.0) was added to the reaction mixture and the resulting mixture was reacted at room temperature for 2 hours to block

excess active groups in the mixture. The obtained mixture was placed on a glass filter (G3) and washed successively with 200 ml of the coupling buffer, 200 ml of an acetate buffer (0.1 M sodium acetate, pH 4, 0.5 M NaCl) and 200 ml of a phosphate buffer (pH 7.0, 0.15 M NaCl) to obtain antibody-bonded Sepharose. The antibody-bonded Sepharose was packed in a column to obtain an affinity column.

After washing the affinity column sufficiently with the phosphate buffer, 1 ml of the antiserum was applied to a column and 500 ml of the phosphate buffer was passed through the column to wash out proteins not adsorbed on the column. Then, 20 ml of 0.1 M glycine-hydrochloric acid (pH 3.0) was passed through the column to elute the adsorbed antibody. After the pH of the eluate was adjusted to 7, the eluate was concentrated and dialyzed against the phosphate buffer to obtain 1 mg/ml of a purified antibody solution.

(Preparation of radioimmunoassay plate)

The antibody solution was diluted 100-fold with the phosphate buffer to a concentration of 10 µg/ml, and added to an assay plate for radioimmunoassay (Falcon 3911, manufactured and sold by Falcon, U.S.A.) in an amount of 100 µl for each well of the plate. The antibody solution was kept at 4 °C for 48 hours so

that the antibody against the NBT-2 membrane protein adheres to the bottom of the plate. The assay plate was then washed sufficiently with a blocking agent (a phosphate buffer containing 3 % BSA) and stored at - 20 °C.

(Radioimmunoassay of tumor cell antigen by  $^{125}\text{I}$ -labeled T cell antigen receptor)

The NBT-2 tumor cell membrane protein fraction was diluted with the blocking agent to prepare a series of solutions having various concentrations. These solutions were separately added to the assay plate having anti-NBT-2 tumor cell protein antibody adhering thereto in an amount of 100  $\mu\text{l}$  for each well. The solutions in the plate were kept at 37 °C for 2 hours and washed sufficiently with the blocking agent. Then, the clone 51-derived  $^{125}\text{I}$ -labeled T cell antigen receptor solution and the blocking agent were added to the solutions in the wells in amounts of 15  $\mu\text{l}$  (6000 cpm) and 90  $\mu\text{l}$ , respectively. The resulting mixtures in the wells were kept at 37 °C for 2 hours. Subsequently, the well was washed sufficiently with the blocking agent, and each well of the plate was cut apart and subjected to measurement of the radioactivity. The results are shown in Table 5.

Table 5

## Radioimmunoassay by T cell antigen receptor

| Dilution of<br>the solutions<br>(fold) |                        | 10   | 100  | 200  | 1000 | 2000 | 10000 |
|--|------------------------|------|------|------|------|------|-------|
| 5                                      | Radioactivity<br>(cpm) | 4530 | 4515 | 4490 | 1115 | 525  | 135   |

The results show that a cell free antigen could be determined by using a labeled T cell antigen receptor.

Example 13

The T cell antigen receptor derived from the clone 51 was obtained in substantially the same manner as in Example 5. To the obtained receptor was bonded a cytotoxin, and its tumor killing activity was evaluated.

(Bonding of a cytotoxin to T cell antigen receptor)

Lysin A chain used as a cytotoxin. The lysin A chain was prepared by a customary method [S. Olsnes, Biochemistry, 12, 3124 (1973)]. The lysin A chain was bonded to the T cell antigen receptor by the method in which N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) is used [Cancer Res. 42, 5209 (1982)].

Illustratively stated, SPDP was added to 0.5 ml of a solution containing the T cell antigen receptor obtained in substantially the same manner as in Example 5. The resulting mixture was kept at 23 °C for 30 min and then the reaction was stopped. Subsequently, the lysin A chain was added to the mixture and a reaction was allowed to proceed at 23 °C for 15 hours to obtain lysin-bonded T cell antigen receptor solution.

(Evaluation of tumor killing activity of cytotoxin-bonded T cell antigen receptor)

10  $10\ \mu\text{l}$  of the above-prepared lysin-bonded T cell antigen receptor solution was added to 200  $\mu\text{l}$  of an RPMI 1640 medium containing 10 v/v% fetal bovine serum and  $2 \times 10^5$  cells/ml of a cell mixture of the human bladder tumor cell line NBT-2 and the human normal lymphocytes suspended therein. After the mixture was cultured for 24 hours, the mixture was subjected to trypan blue staining to determine life (unstained) or death (stained) of the cells in the mixture. As a result, it was found that only the tumor cells were killed and human normal lymphocytes were not killed. The results showed that the cytotoxin-bonded T cell antigen receptor of the present invention had a tumor killing activity.

What is claimed is:

1. A cloned T cell which is capable of recognizing plural kinds of tumor cells.
2. A cloned T cell according to claim 1, which is derived from a member selected from the group consisting of cytotoxic T cells and helper T cells.
3. A cloned T cell according to claim 1, which is a hybridoma comprising a T lymphoma and a T cell capable of recognizing plural kinds of tumor cells.
4. A cloned T cell according to claim 3, wherein said T cell capable of recognizing plural kinds of tumor cells is derived from a member selected from the group consisting of cytotoxic T cells and helper T cells.
5. A cloned T cell according to claim 3, wherein said T lymphoma is an 8-azaguanine resistant strain derived from a cell line selected from the group consisting of human T lymphomas CEM, Jurkat, HPB-ALL, HPB-MLT, Molt-3 and Molt-4.
6. A cloned T cell according to any one of claims 1 to 5, wherein said plural kinds of tumor cells comprise at least two members selected from the group consisting of human tumor



cell lines MKN-1, MKN-7, KATO-III, PC-1, PC-9, PC-10, PC-13, PC-14, C-1, M7609, CaR-1, S-7512, H-1, HLE, HLF, NBT-2, KU-1, KB, W-2, NRC-12, HBC-4, HBC-6, HeLa, HMV-1, HMV-2, GOTO, SYM-I, YS-K and KYM-1.

7. A method for producing a cloned T cell which is capable of recognizing plural kinds of tumor cells, comprising:

- (a) activating lymphocytes by an activator selected from the group consisting of a tumor cell, a lectin, interleukin 2 and mixtures thereof to obtain activated lymphocytes,
- (b) subjecting the activated lymphocytes to cloning in a medium containing interleukin 2 to obtain cloned lymphocytes, and
- (c) subjecting the cloned lymphocytes to screening to isolate a T cell capable of recognizing plural kinds of tumor cells from said cloned lymphocytes.

8. A method according to claim 7, wherein said plural kinds of tumor cells are at least two members selected from the group consisting of human tumor cell lines MKN-1, MKN-7, KATO-III, PC-1, PC-9, PC-10, PC-13, PC-14, C-1, M7609, CaR-1, S7512, H-1, HLE, HLF, NBT-2, KU-1, KB, W-2, NRC-12, HBC-4, HBC-6, HeLa, HMV-1, HMV-2, GOTO, SYM-1, YS-K and KYM-1.

9. A method for producing a hybridoma in accordance with the method of claim 7, which comprises, following step (c) fusing the isolated T cell with a T lymphoma to form a hybridoma comprising said T lymphoma and said T cell capable of recognizing plural kinds of tumor cells.

10. A method for producing a cloned T cell which is capable of recognizing plural kinds of tumor cells, comprising:

- (a) fusing lymphocytes with cells of a T lymphoma to form hybridomas, and
- (b) subjecting the hybridomas to screening to isolate a T cell capable of recognizing plural kinds of tumor cells from said hybridomas.

11. A method according to claim 10, wherein said plural kinds of tumor cells comprise at least two member selected from the group consisting of human tumor cell lines MKN-1, MKN-7, KATO-III, PC-1, PC-9, PC-10, PC-13, PC-14, C-1, M7609, CaR-1, S7512, H-1, HLE, HLF, NBT-2, KU-1, KB, W-2, NRC-12, HBC-4, HBC-6, HeLa, HMV-1, HMV-2, GOTO, SYM-1, YS-K and KYM-1.

12. A T cell antigen receptor which is capable of binding to plural kinds of tumor cells.

13. A T cell antigen receptor according to claim 12, wherein said plural kinds of tumor cells comprise at least two members selected from the group consisting of human tumor cell lines MKN-1, MKN-7, KATO-III, PC-1, PC-9, PC-10, PC-13, PC-14, C-1, M7609, CaR-1, S7512, H-1, HLE, HLF, NBT-2, KU-1, KB, W-2, NRC-12, HBC-4, HBC-6, HeLa, HMV-1, HMV-2, GOTO, SYM-I, YS-K and KYM-1.

14. A T cell antigen receptor which is capable of binding to plural kinds of tumor cells and contains a marker bonded thereto.

15. A T cell antigen receptor which is capable of binding to plural kinds of tumor cells and contains a cytotoxin bonded thereto.

09/803,578